Antios

News

Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its hepatitis B drug candidate, ATI-2173.

News

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.